Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Angiogenesis

Angiogenesis

Products for  Angiogenesis

  1. Cat.No. Product Name Information
  2. GC37975 α2β1 Integrin Ligand Peptide α2β1 Integrin Ligand Peptide interacts with the α2β1 integrin receptor on the cell membrane and mediates extracellular signals into cells. α2β1 Integrin Ligand Peptide Chemical Structure
  3. GC38873 α2β1 Integrin Ligand Peptide TFA α2β1 Integrin Ligand Peptide TFA Chemical Structure
  4. GC68390 α5β1 integrin agonist-1 α5β1 integrin agonist-1 Chemical Structure
  5. GC62380 αvβ1 integrin-IN-1 αvβ1 integrin-IN-1 (Compound C8) is a potent and selective αvβ1 integrin inhibitor with an IC50 of 0.63 nM. αvβ1 integrin-IN-1 Chemical Structure
  6. GC62566 αvβ1 integrin-IN-1 TFA αvβ1 integrin-IN-1 TFA Chemical Structure
  7. GC64932 αvβ5 integrin-IN-1 αvβ5 integrin-IN-1 is a first potent and selective αvβ5 integrin inhibitor (pIC50 = 8.2) . αvβ5 integrin-IN-1 Chemical Structure
  8. GC45269 (±)10(11)-DiHDPA

    (±)10,11-DiHDPE

     (±)10(11)-DiHDPA is produced from cytochrome P450 epoxygenase action on docosahexaenoic acid. (±)10(11)-DiHDPA Chemical Structure
  9. GC41212 (±)10(11)-EpDPA

    (±)10,11-EDP, (±)10,11-EpDPE, (±)10,11-epoxy DPA, (±)10,11-epoxy Docosapentaenoic Acid

     Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)10(11)-EpDPA Chemical Structure
  10. GC40466 (±)11(12)-EET

    (±)11,12-EpETrE

    (±)11(12)-EET is a fully racemic version of the R/S enantiomeric forms biosynthesized from arachidonic acid by cytochrome P450 enzymes.

     (±)11(12)-EET Chemical Structure
  11. GC41648 (±)13(14)-DiHDPA

    13(14)-DiHDPA, 13(14)-DiHDoPE, 13,14-DiHDPE

     (±)13(14)-DiHDPA is a metabolite of docosahexaenoic acid that is produced via oxidation by cytochrome P450 epoxygenases. (±)13(14)-DiHDPA Chemical Structure
  12. GC41191 (±)13(14)-EpDPA

    (±)13,14-EDP, (±)13,14-EpDPE, (±)13,14-epoxy DPA, (±)13,14-epoxy Docosapentaenoic Acid

     Cytochrome P450 metabolism of polyunsaturated fatty acids produces numerous bioactive epoxide regioisomers. (±)13(14)-EpDPA Chemical Structure
  13. GC41653 (±)16(17)-DiHDPA (±)16(17)-DiHDPA is produced from cytochrome P450 epoxygenase action on docosahexaenoic acid. (±)16(17)-DiHDPA Chemical Structure
  14. GC41655 (±)19(20)-EDP Ethanolamide

    19,20-DHEA epoxide, 19,20-epoxy Docosapentaenoic Acid Ethanolamide, 19,20-EDP-EA, 19,20-EDP epoxide

     (±)19(20)-EDP ethanolamide is an ω-3 endocannabinoid epoxide and cannabinoid (CB) receptor agonist (EC50s = 108 and 280 nM for CB1 and CB2, respectively). (±)19(20)-EDP Ethanolamide Chemical Structure
  15. GC41203 (±)7(8)-EpDPA

    (±)7,8-EDP, (±)7,8-EpDPE, (±)7,8-epoxy DPA, (±)7,8-epoxy Docosapentaenoic Acid

     Docosahexaenoic acid is the most abundant ω-3 fatty acid in neural tissues, especially in the brain and retina. (±)7(8)-EpDPA Chemical Structure
  16. GC34069 (±)-Zanubrutinib ((±)-BGB-3111) (±)-Zanubrutinib ((±)-BGB-3111) ((±)-BGB-3111) is a potent, selective and orally available Bruton's tyrosine kinase (Btk) inhibitor. (±)-Zanubrutinib ((±)-BGB-3111) Chemical Structure
  17. GC67857 (R)-Elsubrutinib

    (R)-ABBV-105

     (R)-Elsubrutinib Chemical Structure
  18. GC69837 (R/S)-Alicaforsen

    (R/S)-ISIS-2302

    (R/S)-Alicaforsen is the racemic form of Alicaforsen, which consists of both R and S configurations. Alicaforsen is a 20-base length antisense oligonucleotide that inhibits the production of ICAM-1, an important adhesion molecule involved in the migration and transport process of white blood cells to inflammatory sites.

     (R/S)-Alicaforsen Chemical Structure
  19. GC63797 (S)-Sunvozertinib

    (S)-DZD9008

     (S)-Sunvozertinib ((S)-DZD9008), the S-enantiomer of Sunvozertinib, shows inhibitory activity against EGFR exon 20 NPH and ASV insertions, EGFR L858R/T790M mutation and Her2 exon20 YVMA insertion (IC50=51.2 nM, 51.9 nM, 1 nM, and 21.2 nM, respectively). (S)-Sunvozertinib also inhibits BTK. (S)-Sunvozertinib Chemical Structure
  20. GC49808 12-methyl Tridecanoic Acid

    iso-14:0, iso-C14:0, 12-MTA

     A methylated fatty acid 12-methyl Tridecanoic Acid Chemical Structure
  21. GC46474 18-Deoxyherboxidiene

    RQN-18690A

     A bacterial metabolite with antiangiogenic activity 18-Deoxyherboxidiene Chemical Structure
  22. GC16195 2,4-DPD

    2,4-Diethylpyridine dicarboxylate

     Diethyl pyridine-2,4-dicarb is a potent prolyl 4-hydroxylase-directed proinhibitor. 2,4-DPD Chemical Structure
  23. GC17368 2-Furoyl-LIGRLO-amide Protease-activated receptor agonist 2-Furoyl-LIGRLO-amide Chemical Structure
  24. GC38731 2-Furoyl-LIGRLO-amide TFA 2-Furoyl-LIGRLO-amide TFA is a potent and selective proteinase-activated receptor 2 (PAR2) agonist with a pD2 value of 7.0. 2-Furoyl-LIGRLO-amide TFA Chemical Structure
  25. GC14282 3-acetyl-11-keto-β-Boswellic Acid

    3-O-acetyl-11-keto-β-Boswellic acid,AKBA

     3-acetyl-11-keto-β-Boswellic Acid (Acetyl-11-keto-β-boswellic acid) is an active triterpenoid compound from the extract of Boswellia serrate and a novel Nrf2 activator. 3-acetyl-11-keto-β-Boswellic Acid Chemical Structure
  26. GC46583 3-Amino-2,6-Piperidinedione

    α-Aminoglutarimide, 3-Aminoglutarimide, Glutamimide

     An active metabolite of (±)-thalidomide 3-Amino-2,6-Piperidinedione Chemical Structure
  27. GC49562 4-methoxy Estrone

    4-MeOE1, 4-methoxy E1

     An active metabolite of estrone 4-methoxy Estrone Chemical Structure
  28. GC15557 A 205804 E-selectin/ICAM-1 expression inhibitor A 205804 Chemical Structure
  29. GC15192 A 286982 A LFA-1/ICAM-1 interaction inhibitor A 286982 Chemical Structure
  30. GC65597 Abciximab

    C7E3

    Abciximab (C7E3), a chimeric mouse/human monoclonal antibody, is a glycoprotein (GP) IIb/IIIa inhibitor.

     Abciximab Chemical Structure
  31. GC68594 Abituzumab

    EMD 525797; DI17E6

    Abituzumab (DI17E6) is a humanized monoclonal antibody (IgG2 type) against integrin αV. Abituzumab can effectively reduce the phosphorylation of FAK, Akt and ERK. Abituzumab can be used in cancer research, especially for prostate cancer.

     Abituzumab Chemical Structure
  32. GC14831 AC 264613 PAR2 agonist,potent and selective AC 264613 Chemical Structure
  33. GC15290 AC 55541 PAR2 agonist,potent and selective AC 55541 Chemical Structure
  34. GC60551 Acalabrutinib D4

    ACP-196-d4

     Acalabrutinib D4 Chemical Structure
  35. GC35230 Acetylarenobufagin Acetylarenobufagin is a steroidal hypoxia inducible factor-1 (HIF-I) modulator. Acetylarenobufagin Chemical Structure
  36. GC15453 ACP-196

    ACP-196

     ACP-196 (ACP-196) is an orally active, irreversible, and highly selective second-generation BTK inhibitor. ACP-196 binds covalently to Cys481 in the ATP-binding pocket of BTK. ACP-196 demonstrates potent on-target effects and efficacy in mouse models of chronic lymphocytic leukemia (CLL). ACP-196 Chemical Structure
  37. GC32083 Acriflavine Acriflavine is a fluorescent dye for labeling high molecular weight RNA. Acriflavine Chemical Structure
  38. GC12487 Adaptaquin

    HIF prolyl hydroxylase inhibitor

     HIF-prolyl hydroxylase-2 (PHD2) inhibitor Adaptaquin Chemical Structure
  39. GC33416 AFP464

    NSC710464 free base

     AFP464 (NSC710464 free base), is an active HIF-1α inhibitor with an IC50 of 0.25 μM, also is a potent aryl hydrocarbon receptor (AhR) activator. AFP464 Chemical Structure
  40. GC49799 Apatinib-d8 An internal standard for the quantification of apatinib Apatinib-d8 Chemical Structure
  41. GC31679 ARQ 531

    MK-1026

    ARQ 531 (MK-1026) is a reversible non-covalent and orally active inhibitor of Bruton’s Tyrosine Kinase (BTK), with IC50s of 0.85 nM and 0.39 nM for WT-BTK and C481S-BTK, respectively.

     ARQ 531 Chemical Structure
  42. GC34133 ATN-161 ATN-161 is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. ATN-161 Chemical Structure
  43. GC33837 ATN-161 trifluoroacetate salt (ATN-161 TFA salt)

    Ac-PHSCN-NH2, PHSCN Peptide

     ATN-161 trifluoroacetate salt (ATN-161 TFA salt) is a novel integrin α5β1 antagonist, which inhibits angiogenesis and growth of liver metastases in a murine model. ATN-161 trifluoroacetate salt (ATN-161 TFA salt) Chemical Structure
  44. GC63658 Atopaxar Atopaxar (E5555) is a potent, orally active, selective and reversible thrombin receptor protease-activated receptor-1 (PAR-1) antagonist. Atopaxar Chemical Structure
  45. GC70685 Atuzabrutinib Atuzabrutinib (SAR 444727) is a potent, selective reversible inhibitor of Btk (Bruton's tyrosine kinase) inhibitor. Atuzabrutinib Chemical Structure
  46. GC13562 AVL-292

    AVL292;AVL 292

     A covalent BTK inhibitor AVL-292 Chemical Structure
  47. GC42887 Axitinib Sulfoxide Axitinib sulfoxide is a major inactive metabolite of the tyrosine kinase inhibitor axitinib. Axitinib Sulfoxide Chemical Structure
  48. GC46899 Axitinib-13C-d3

    AG-013736-13C-d3

     An internal standard for the quantification of axitinib Axitinib-13C-d3 Chemical Structure
  49. GC18152 AZ-3451

    A potent, and selective PAR2 antagonist with Kd of 13.5 nM.

     AZ-3451 Chemical Structure
  50. GC65312 AZ8838 AZ8838 is a potent, competitive, allosteric, orally active non-peptide small molecule antagonist of PAR2 with a pKi of 6.4 for hPAR2. AZ8838 Chemical Structure
  51. GC12698 BAY 87-2243 A HIF-1 inhibitor,potent and selective BAY 87-2243 Chemical Structure
  52. GC68754 Bersanlimab

    BI-505

    Bersanlimab (BI-505) is a fully human monoclonal antibody that targets intercellular adhesion molecule-1 (ICAM-1 or CD54). Bersanlimab has anti-cancer effects.

     Bersanlimab Chemical Structure
  53. GC65909 Bexotegrast

    PLN-74809

     Bexotegrast is a potent inhibitor of αΝβ6 integrin. Bexotegrast can be used for researching fibrosis such as idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) (extracted from patent WO2020210404A1, compound 5). Bexotegrast Chemical Structure
  54. GC63846 BIIB091 BIIB091 is a highly selective, reversible and orally active BTK inhibitor for treating autoimmune diseases. BIIB091 Chemical Structure
  55. GC17560 BIO 1211 An α4β1 inhibitor,selective and high affinity BIO 1211 Chemical Structure
  56. GC14208 BIO 5192 α4β1 inhibitor BIO 5192 Chemical Structure
  57. GC60077 BIO5192 hydrate BIO5192 hydrate is a selective and potent integrin α4β1 (VLA-4) inhibitor (Kd<10 pM). BIO5192 hydrate Chemical Structure
  58. GC50078 BIRT 377 Potent negative allosteric modulator of LFA-1 BIRT 377 Chemical Structure
  59. GC68373 BLK-IN-2 BLK-IN-2 Chemical Structure
  60. GC18717 BMS 986120 A selective PAR4 antagonist BMS 986120 Chemical Structure
  61. GC62872 BMS-587101 BMS-587101 is a potent and orally active antagonist of leukocyte function associated antigen-1 (LFA-1). BMS-587101 Chemical Structure
  62. GC38893 BMS-688521 BMS-688521 is a highly potent, orally active inhibitor of the LFA-1/ICAM interaction, with an IC50 of 2.5 nM in the adhesion assay and an IC50 of 60 nM in the MLR assay. BMS-688521 Chemical Structure
  63. GC31760 BMS-935177 BMS-935177 is a potent and selective reversible inhibitor of Bruton’s tyrosine kinase (Btk) with an IC50 of 3 nM. BMS-935177 Chemical Structure
  64. GC31713 BMS-986142 A BTK inhibitor BMS-986142 Chemical Structure
  65. GC32844 BMS-986195

    BMS-986195

     BMS-986195 (BMS-986195) is a highly potent, selective covalent, irreversible inhibitor of Bruton's tyrosine kinase (BTK), with an IC50 of 0.1 nM. BMS-986195 Chemical Structure
  66. GC11063 BMX-IN-1

    BMX Inhibitor 1

     A selective BMX and BTK inhibitor BMX-IN-1 Chemical Structure
  67. GC50325 BOP BOP is a potent and selective dual α9β1/α4β1 integrin inhibitor with Kd values in the picomolar range. BOP Chemical Structure
  68. GC19333 BTK IN-1

    BTK-IN-1

     BTK IN-1 is a potent BTK inhibitor, with an IC50 of <100 nM. BTK IN-1 Chemical Structure
  69. GC35561 Btk inhibitor 1 Btk inhibitor 1 is a racemate of IBT6A. IBT6A is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Btk inhibitor 1 Chemical Structure
  70. GC35562 Btk inhibitor 1 hydrochloride Btk inhibitor 1 hydrochloride Chemical Structure
  71. GC10924 Btk inhibitor 1 R enantiomer Btk inhibitor 1 R enantiomer is an impurity of Ibrutinib. Btk inhibitor 1 R enantiomer can be used in synthesis of Btk inhibitor 1 R enantiomer Ibrutinib dimer and Btk inhibitor 1 R enantiomer adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Btk inhibitor 1 R enantiomer Chemical Structure
  72. GC35563 Btk inhibitor 1 R enantiomer hydrochloride Btk inhibitor 1 R enantiomer hydrochloride is an impurity of Ibrutinib. IBT6A can be used in synthesis of IBT6A Ibrutinib dimer and IBT6A adduct. Ibrutinib is a selective, irreversible Btk inhibitor with an IC50 of 0.5 nM. Btk inhibitor 1 R enantiomer hydrochloride Chemical Structure
  73. GC67940 BTK inhibitor 10 BTK inhibitor 10 Chemical Structure
  74. GC62498 BTK inhibitor 17 BTK inhibitor 17 is a potent and orally active irreversible BTK inhibitor with an IC50 of 2.1 nM. BTK inhibitor 17 Chemical Structure
  75. GC64360 BTK inhibitor 18 BTK inhibitor 18 is a potent, selective,orally active and covalent Btk inhibitor with a IC50 of 142 nM. BTK inhibitor 18 Chemical Structure
  76. GC32007 Btk inhibitor 2

    BGB-3111 analog

     Btk inhibitor 2 (BGB-3111 analog) is a Bruton's tyrosine kinase (BTK) inhibitor extracted from patent US 20170224688 A1. Btk inhibitor 2 Chemical Structure
  77. GC50075 BTT 3033 Selective inhibitor of integrin α2β1 BTT 3033 Chemical Structure
  78. GC38128 c(phg-isoD-G-R-(NMe)k) TFA c(phg-isoD-G-R-(NMe)k) TFA Chemical Structure
  79. GC65455 c(phg-isoDGR-(NMe)k) c(phg-isoDGR-(NMe)k) is a selective and potent α5β1-integrin ligand with an IC50 of 2.9 nM. c(phg-isoDGR-(NMe)k) Chemical Structure
  80. GC49433 Capsiate A capsaicin analog with diverse biological activities Capsiate Chemical Structure
  81. GC32042 Carotegrast

    HCA2969

     Carotegrast is an orally available α4 integrin receptor inhibitor with anti-inflammatories activities. Carotegrast Chemical Structure
  82. GC62143 Carotegrast methyl

    AJM300

     Carotegrast methyl (AJM300) is an orally active and selective α4 integrin antagonist. Carotegrast methyl Chemical Structure
  83. GC43198 CAY10717 CAY10717 is a multi-targeted kinase inhibitor that exhibits greater than 40% inhibition of 34 of 104 kinases in an enzymatic assay at a concentration of 100 nM. CAY10717 Chemical Structure
  84. GC68856 Certepetide

    CEND-1; iRGD

    Certepetide (CEND-1) is a dual-function cyclic peptide (also known as iRGD). Certepetide is a penetrable tumor peptide that interacts with alpha-v integrins through its RGD motif and activates neuropilin-1 (NRP-1), thereby transforming the solid tumor microenvironment into temporary active molecular channels. Certepetide can accumulate in tumors and can be used for research on pancreatic cancer and other solid tumors.

     Certepetide Chemical Structure
  85. GC33064 CG-806 (Luxeptinib)

    CG-806

     CG-806 (Luxeptinib) (CG-806) is an orally active, reversible, first-in-class, non-covalent and potent pan-FLT3/pan-BTK inhibitor. CG-806 (Luxeptinib) induces cell cycle arrest, apoptosis or autophagy in acute myeloid leukemia cells. CG-806 (Luxeptinib) Chemical Structure
  86. GC13365 CGI-1746 A potent, selective BTK inhibitor CGI-1746 Chemical Structure
  87. GC35683 CHMFL-BTK-01 CHMFL-BTK-01 (compound 9) is a highly selective irreversible BTK inhibitor, with an IC50 of 7 nM. CHMFL-BTK-01 (compound 9) potently inhibited BTK Y223 auto-phosphorylation. CHMFL-BTK-01 Chemical Structure
  88. GC35684 CHMFL-EGFR-202 CHMFL-EGFR-202 is a potent, irreversible inhibitor of epidermal growth factor receptor (EGFR) mutant kinase, with IC50s of 5.3 nM and 8.3 nM for drug-resistant mutant EGFR T790M and WT EGFR kinases, respectively. CHMFL-EGFR-202 exhibits ?10-fold selectivity for EGFR L858R/T790M against the EGFR wild-type in cells. CHMFL-EGFR-202 adopts a covalent “DFG-in-C-helix-out” inactive binding conformation with EGFR, with strong antiproliferative effects against EGFR mutant-driven nonsmall-cell lung cancer (NSCLC) cell lines. CHMFL-EGFR-202 Chemical Structure
  89. GC13559 Cilengitide

    EMD 121974

     Integrin inhibitor for αvβ3 and αvβ5 Cilengitide Chemical Structure
  90. GC61520 Cilengitide TFA

    EMD 121974 TFA

     Cilengitide is a potent and selective integrin inhibitor for αvβ3 and αvβ5 receptor, with IC50 values of 4 nM and 79 nM, respectively. Cilengitide TFA Chemical Structure
  91. GC45880 Cimetidine-d3 An internal standard for the quantification of cimetidine Cimetidine-d3 Chemical Structure
  92. GC13439 CNX-774 BTK inhibitor, orally active, irreversible and selective CNX-774 Chemical Structure
  93. GC17631 Combretastatin A4

    CA4, Combretastatin A4, CRC 8709

     tubulin polymerization inhibitor Combretastatin A4 Chemical Structure
  94. GN10535 Cucurbitacin B

    Cuc B, NSC 49451, NSC 144154

     Cucurbitacin B Chemical Structure
  95. GC13050 CWHM-12 An inhibitor of αV integrins CWHM-12 Chemical Structure
  96. GC17610 Cyclo (-RGDfK)

    Cyclo(-Arg-Gly-Asp-D-Phe-Lys)

     An inhibitor of αvβ3 integrin Cyclo (-RGDfK) Chemical Structure
  97. GA21306 Cyclo(-Arg-Gly-Asp-D-Tyr-Lys) c(RGDyK) has been radioiodinated or modified with chelators for use as radiopharmaceutical. Cyclo(-Arg-Gly-Asp-D-Tyr-Lys) Chemical Structure
  98. GC60117 Cyclo(-RGDfK) TFA Cyclo(-RGDfK) TFA is a potent and selective inhibitor of the αvβ3 integrin, with an IC50 of 0.94 nM. Cyclo(-RGDfK) TFA potently targets tumor microvasculature and cancer cells through the specific binding to the αvβ3 integrin on the cell surface. Cyclo(-RGDfK) TFA Chemical Structure
  99. GC68921 Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA

    Cyclo(RGDfC) TFA

    Cyclo(Arg-Gly-Asp-D-Phe-Cys) (Cyclo RGDfC) TFA is a cyclic RGD peptide with high affinity for αvβ3 integrin, which can disrupt cell adhesion. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA inhibits the expression of pluripotency genes in embryonic stem cells (ESC), and suppresses the tumorigenic potential of mESCs in vivo. Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA can be used for tumor-related research.

     Cyclo(Arg-Gly-Asp-D-Phe-Cys) TFA Chemical Structure
  100. GC34141 Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Cyclo(Arg-Gly-Asp-D-Phe-Val) (TFA) is an inhibitor of integrin αvβ3, with antitumor activity. Cyclo(Arg-Gly-Asp-D-Phe-Val) TFA Chemical Structure
  101. GC30111 Cyclo(RADfK) Cyclo(RADfK) is a selective α(v)β(3) integrin ligand that has been extensively used for research, therapy, and diagnosis of neoangiogenesis. Cyclo(RADfK) Chemical Structure

Items 1 to 100 of 303 total

per page
  1. 1
  2. 2
  3. 3
  4. 4

Set Descending Direction